Aspirin in the prevention and treatment of venous thromboemblism

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 7, 2006, Pages 1470-1475

  Hovens, M M C ^a   Snoep, J D ^a   Tamsma, J T ^a   Huisman, M V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aspirin; Prevention; Review; Venoust thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; DANAPAROID; DIPYRIDAMOLE; ENOXAPARIN; HEPARIN; HYDROXYCHLOROQUINE; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; REVIPARIN; REVIPARIR; TICLOPIDINE; WARFARIN;

AVIATION; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EXPERIMENTAL MODEL; HUMAN; IN VIVO STUDY; INCIDENCE; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SURGICAL PATIENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS PREVENTION; THROMBUS; VENOUS THROMBOEMBOLISM;

ASPIRIN; HUMANS; INCIDENCE; RECURRENCE; THROMBOEMBOLISM; TRAVEL; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 33745269206     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01928.x     Document Type: Review

References (40)

1. Antitrombotic Trialists' Combination. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Clagett GP, Schneider P, Rosoff CB, Salzman EW. The influence of aspirin on postoperative platelet kinetics and venous thrombosis. Surgery 1975; 77: 61-74.
3. Renney JT, O'Sullivan EF, Burke PF. Prevention of postoperative deep vein thrombosis with dipyridamole and aspirin. Br Med J 1976; 1: 992-4.
4. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 338S-400S.
5. Anderson Jr FA, Hirsh J, White K, Fitzgerald Jr RH. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: Findings from the Hip and Knee Registry. Chest 2003; 124: 349S-56S.
6. BBC news [updated 2003 February 8; Accessed 26 October 2005]. Available at: http://news.bbc.co.uk/1/hi/health/medical_notes/c-d/986364.stm.
7. Cervantes J, Rojas G. Virchow's legacy: Deep vein thrombosis and pulmonary embolism. World J Surg 2005; 29: S30-4.
8. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (Am Soc Hematol Educ Program) 2004; 439-56.
9. Sevitt S. Structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol 1974; 27: 517-28.
10. Kim Y, Nakase H, Nagata K, Sakaki T, Maeda M, Yamamoto K. Observation of arterial and venous thrombus formation by scanning and transmission electron microscopy. Acta Neurochir (Wien) 2004; 146: 45-51.
11. Myers Jr DD, Rectenwald JE, Bedard PW, Kaila N, Shaw GD, Schaub RG, Farris DM, Hawley AE, Wrobleski SK, Henke PK, Wakefield TW. Decreased venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg 2005; 42: 329-36.
12. Todd MH, Cragg DB, Forrest JB, Ali M, McDonald JW. The involvement of prostaglandins and thromboxanes in the response to pulmonary embolism in anaesthetized rabbits and isolated perfused lungs. Thromb Res 1983; 30: 81-90.
13. Klotz TA, Cohn LS, Zipser RD. Urinary excretion of thromboxane B2 in patients with venous thromboembolic disease. Chest 1984; 85: 329-35.
14. Smulders YM. Contribution of pulmonary vasoconstriction to haemodynamic instability after acute pulmonary embolism. Implications for treatment? Neth J Med 2001; 58: 241-7.
15. Utsunomiya T, Krausz MM, Levine L, Shepro D, Hechtman HB. Thromboxane mediation of cardiopulmonary effects of embolism. J Clin Invest 1982; 70: 361-8.
16. Todd MH, Forrest JB, Cragg DB. The effects of aspirin and methysergide, singly and in combination, on systemic haemodynamic responses to pulmonary embolism. Can Anaesth Soc J 1981; 28: 373-80.
17. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998; 158: 585-93.
18. Clagett GP, Anderson Jr FA, Geerts W, Heit JA, Knudson M, Lieberman JR, Merli GJ, Wheeler HB. Prevention of venous thromboembolism. Chest 1998; 114: 531S-60S.
19. O'Brien JR. Effects of salicylates on human platelets. Lancet 1968; 1: 779-83.
20. Steering Committee MRC. Effect of aspirin on postoperative venous thrombosis. Report of the Steering Committee of a trial sponsored by the Medical Research Council. Lancet 1972; 2: 441-5.
21. Antitrombotic Trialists' Combination. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 235-46.
22. Cohen AT, Skinner JA, Kakkar VV. Antiplatelet treatment for thromboprophylaxis: A step forward or backwards? BMJ 1994; 309: 1213-5.
23. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271: 1780-5.
24. Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, Jay RM, Leclerc J, Neemeh JA, Turpie AG. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 1996; 93: 80-4.
25. Gehling H, Giannadakis K, Lefering R, Hessmann M, Achenbach S, Gotzen L. Prospective randomized pilot study of ambulatory prevention of thromboembolism. 2 times 500 mg aspirin (ASS) vs clivarin 1750 (NMH). Unfallchirurg 1998; 101: 42-9.
26. Lotke PA, Palevsky H, Keenan AM, Meranze S, Steinberg ME, Ecker ML, Kelley MA. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res 1996; 324: 251-8.
27. Powers PJ, Gent M, Jay RM, Julian DH, Turpie AG, Levine M, Hirsh J. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989; 149: 771-4.
28. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302.
29. Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002; 162: 1465-71.
30. Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboembolic disease: A case-control study. Chest 1999; 115: 440-4.
31. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: The Sirius study. Arch Intern Med 2000; 160: 3415-20.
32. Lapostolle F, Surget V, Borron SW, Desmaizieres M, Sordelet D, Lapandry C, Cupa M, Adnet F. Severe pulmonary embolism associated with air travel. N Engl J Med 2001; 345: 779-83.
33. Cesarone MR, Belcaro G, Nicolaides AN, Incandela L, De S, Geroulakos G, Lennox A, Myers KA, Moia M, Ippolito E, Winford M. Venous thrombosis from air travel: The LONFLIT3 study - prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: A randomized trial. Angiology 2002; 53: 1-6.
34. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-28S.
35. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med 2000; 160: 761-8.
36. Kearon C. Long-term management of patients after venous thromboembolism. Circulation 2004; 110: I10-8.
37. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336: 393-8.
38. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-64S.
39. Agnelli G, Becattini C. Warfasa trial [homepage on the Internet]. Clinical trials.gov [updated 2005 May 21; cited 2005 October 26]. Available at: http://www.clinicaltrials.gov/ct/show/NCT00222677?order=1
40. Brighton T, Eikelboom J, Gallus A, Ockelford P, Becattini C, Agnelli G, Simes R. Low-dose aspirin for secondary prophylaxis of vein thrombosis - a prospectively planned meta-analysis. J Thromb Haemost 2005; 3 (Suppl. 1): P2202 (Abstract).